After axing a top drug, Millendo bags a PhII replacement with biotech buyout
Millendo Therapeutics has acquired a small French biotech named Alizé Pharma SAS ̶ and its Phase II obesity-related drug ̶ in a deal that helps …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
